Ethnic and racial differences in patients with Ewing sarcoma.

PubWeight™: 1.12‹?› | Rank: Top 10%

🔗 View Article (PMC 2819622)

Published in Cancer on February 15, 2010

Authors

Jennifer Worch1, Katherine K Matthay, John Neuhaus, Robert Goldsby, Steven G DuBois

Author Affiliations

1: Department of Pediatrics, University of California at San Francisco School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143-0106, USA.

Articles citing this

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One (2011) 2.13

The epidemiology of sarcoma. Clin Sarcoma Res (2012) 1.22

Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol Biomarkers Prev (2011) 1.04

Imaging appearance of bone tumors of the maxillofacial region. World J Radiol (2011) 0.96

EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genet (2012) 0.94

Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer (2011) 0.87

Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group. PLoS One (2014) 0.87

Disease control after reduced volume conformal and intensity modulated radiation therapy for childhood craniopharyngioma. Int J Radiat Oncol Biol Phys (2012) 0.87

Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol (2012) 0.86

Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatr Blood Cancer (2015) 0.80

EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma. Front Oncol (2015) 0.80

Anti-Epileptic Drug Targets Ewing Sarcoma. J Pharm Sci Pharmacol (2014) 0.78

Ewing's Sarcoma and Second Malignancies. Sarcoma (2010) 0.78

Microsatellites with macro-influence in ewing sarcoma. Genes (Basel) (2012) 0.76

Outcomes of 50 Patients With Ewing Sarcoma Family of Tumors Treated at a Single Institution in Taiwan. Medicine (Baltimore) (2016) 0.75

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors. Korean J Pediatr (2013) 0.75

Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports. Sarcoma (2015) 0.75

Comparison of Latino and non-Latino patients with Ewing sarcoma. Pediatr Blood Cancer (2013) 0.75

Articles cited by this

Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49

Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst (2002) 6.64

The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev (1999) 5.49

Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer (2006) 4.71

Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15

Bone cancers. Cancer (1995) 3.17

Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. JAMA (2003) 3.07

Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA (2003) 2.77

Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood (2002) 2.17

Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer (2008) 2.04

Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol (2001) 2.01

Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization, and health-related behaviors from the childhood cancer survivor study. J Clin Oncol (2005) 1.59

Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California. Cancer Epidemiol Biomarkers Prev (2006) 1.51

Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer (2001) 1.18

Influence of race and socioeconomic status on outcome of children treated for childhood acute lymphoblastic leukemia. Curr Opin Pediatr (2004) 1.14

The geographic variation of the incidence of malignant primary bone tumors in Sweden. J Bone Joint Surg Am (1974) 1.11

Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl) (1999) 1.07

Pharmacogenomics in admixed populations. Trends Pharmacol Sci (2005) 1.04

Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. Radiother Oncol (1987) 0.96

Rarity of Ewing's sarcoma in China. Lancet (1980) 0.94

Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients. Ann Oncol (2002) 0.93

Rarity of Ewing's sarcoma among U.S. Negro children. Lancet (1970) 0.88

Articles by these authors

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain (2011) 9.90

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34

Saw palmetto for benign prostatic hyperplasia. N Engl J Med (2006) 4.99

Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol (2008) 2.94

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42

Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol (2005) 2.36

Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology (2011) 2.35

Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2010) 2.00

Retinoid therapy of high-risk neuroblastoma. Cancer Lett (2003) 1.97

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91

Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med (2012) 1.89

Symptoms experienced by intensive care unit patients at high risk of dying. Crit Care Med (2010) 1.85

Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2013) 1.84

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol (2011) 1.79

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol (2007) 1.73

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 1.70

Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer (2011) 1.67

Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer (2006) 1.66

Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in survivors of childhood cancer: a report from the Children's Oncology Group. Arch Pediatr Adolesc Med (2007) 1.62

Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol (2011) 1.62

Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol (2005) 1.60

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol (2008) 1.56

Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2012) 1.55

Impact of brief or extended exercise training on the benefit of a dyspnea self-management program in COPD. J Cardiopulm Rehabil (2005) 1.54

Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci (2006) 1.52

Language networks in semantic dementia. Brain (2009) 1.50

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med (2010) 1.47

Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics (2007) 1.42

Challenge of assessing symptoms in seriously ill intensive care unit patients: can proxy reporters help? Crit Care Med (2012) 1.42

Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer (2013) 1.40

Neuroblastoma: biology and staging. Curr Oncol Rep (2009) 1.40

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol (2012) 1.37

Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain (2008) 1.36

Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer (2003) 1.35

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol (2008) 1.35

Spinal dural arteriovenous fistulae: clinical features and long-term results. Neurosurgery (2008) 1.32

Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer (2010) 1.30

Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys (2003) 1.30

Performance in specific language tasks correlates with regional volume changes in progressive aphasia. Cogn Behav Neurol (2007) 1.28

Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration. J Neurosci (2006) 1.25

The Effects of Age and HIV on Neuropsychological Performance. J Int Neuropsychol Soc (2010) 1.25

Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med (2013) 1.25

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol (2009) 1.25

An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord (2009) 1.25

Alcohol consumption patterns and risk factors among childhood cancer survivors compared to siblings and general population peers. Addiction (2008) 1.22

Identification of patient subgroups and risk factors for persistent breast pain following breast cancer surgery. J Pain (2012) 1.22

Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol (2009) 1.21

Identification of distinct depressive symptom trajectories in women following surgery for breast cancer. Health Psychol (2011) 1.19

Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol (2008) 1.18

Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. Eur J Nucl Med Mol Imaging (2008) 1.14

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer (2003) 1.13

Associations between pro- and anti-inflammatory cytokine genes and breast pain in women prior to breast cancer surgery. J Pain (2012) 1.12

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia (2008) 1.11

Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity. Am J Respir Crit Care Med (2010) 1.09

Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg (2004) 1.08

Placebo adherence and its association with morbidity and mortality in the studies of left ventricular dysfunction. J Gen Intern Med (2010) 1.08

Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol (2012) 1.07

Safety and efficacy of citrus aurantium for weight loss. Am J Cardiol (2004) 1.06

Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer (2009) 1.06

Type 2 diabetes and 10-year risk of dementia and cognitive impairment among older Mexican Americans. Diabetes Care (2013) 1.04

The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett (2005) 1.04

Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol Biomarkers Prev (2011) 1.04

Magnetic resonance imaging correlates of set shifting. J Int Neuropsychol Soc (2007) 1.03

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett (2011) 1.03

Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol (2009) 1.03

Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium. Pediatr Blood Cancer (2013) 1.03

Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLoS One (2013) 1.02

Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer (2010) 1.02

Colonoscopy after CT diagnosis of diverticulitis to exclude colon cancer: a systematic literature review. Radiology (2012) 1.02

Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res (2011) 1.02

Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs (2004) 1.01

Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen (2010) 1.01

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol (2004) 1.01

Changes in children's reports of symptom occurrence and severity during a course of myelosuppressive chemotherapy. J Pediatr Oncol Nurs (2010) 1.01

Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer (2009) 1.00

Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys (2010) 1.00

Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol (2009) 1.00

Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer (2005) 0.99

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol (2003) 0.99

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. Cancer Chemother Pharmacol (2008) 0.99

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol (2002) 0.98

Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw (2014) 0.98

Binomial regression with misclassification. Biometrics (2003) 0.98

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res (2012) 0.97

Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. Intensive Care Med (2014) 0.97

Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys (2009) 0.97

Central obesity, leptin and cognitive decline: the Sacramento Area Latino Study on Aging. Dement Geriatr Cogn Disord (2012) 0.95

Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer (2008) 0.95